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Abstract 
 
Objective 
The relationship between conventional indicators of Alzheimer’s disease (AD) progression and 
quality of life (QoL) outcomes is unclear. Dependence on others has been recommended as a 
unifying construct in defining AD severity. This study examined the relationship between indicators 
of disease severity (including dependence) and changes in QoL and utility over 18-months. 
Methods 
A multi-centre, cohort study was conducted across 18 UK sites.  One hundred and forty five patients 
with possible/probable AD and their caregivers completed assessments of disease severity 
(Dependence Scale, Mini-Mental State Examination, Neuropsychiatric Inventory, Disability 
Assessment for Dementia), dementia-specific QoL (DEMQOL, DEMQOL-Proxy) and generic health-
related utility (EQ-5D) at both time points.  
Results 
There was evidence of individual change in QoL over 18 months, with over 50% of patients reporting 
either maintenance or improvement of life quality. The EQ-5D proxy suggested a mean decline in 
QoL whilst the DEMQOL-Proxy indicated overall improvement. In the subsample of people who self-
reported QoL and utility, no mean change was evident. Changes in dependence did not explain 
changes on any QoL or utility outcome.  There was a weak association between the EQ-5D proxy and 
changes in cognition, whereas changes on the DEMQOL-Proxy were partly explained by changes in 
behavioural disturbance. 
Conclusions 
The natural progression of AD over 18-months does not lead to inevitable decline in QoL or utility. 
There are no clear or consistent direct relationships between changes in disease severity and QoL 
outcomes. The impact of increasing dependence and worsening disease severity is likely buffered by 
a combination of psychological, social and environmental factors.   
Key words: Dementia, utility, wellbeing, disease severity, DEMQOL, EQ-5D 
 
Key messages:  
 
 QoL and utility do not inevitably decline as dementia progresses. 
 There are no clear and consistent relationships between markers of disease severity and QoL 
change. 
 The choice of measure may lead to different conclusions about the size, direction and causes 
of QoL and utility change. 
 A better understanding is needed of the mechanisms which allow individuals to report a 
maintenance or improvement of QoL and utility over time. 
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Introduction 
 
Within the last decade, cohort studies have explored changes in patient and proxy reports of QoL in 
relation to the progression of AD. One of the most consistent findings from these studies is the lack 
of detectable change in QoL when measured at the group level (Selwood et al., 2005; Missotten et 
al., 2007; Hoe et al., 2009; Livingston et al., 2012; Heggie et al., 2012). Although there is evidence of 
considerable variation in individual QoL ratings over periods ranging from 20 weeks (Hoe et al., 
2009) to 2 years (Missotten et al., 2007), consistent group-level changes are not apparent for either 
self-report or proxy ratings of QoL. The few studies that have detected group-level decline in QoL 
over time have often found only small effect sizes and large individual variation, with almost half of 
patients reporting stable or improved levels of QoL (Lyketsos et al., 2003; Vogel et al., 2012). 
Baseline severity may have contributed to the differences observed across the longitudinal studies 
as the 3-year follow up study by Vogel et al was conducted in patients diagnosed early in their 
disease, when decline may be easier to detect. 
 
Cohort studies have also yet to provide any clarity in determining the factors associated with 
changes in QoL outcomes. Over a one-year period, Jonsson et al. (2006) found that a decline in proxy 
ratings of utility was associated with worsening cognition and neuropsychiatric symptoms, whilst 
Vogel et al. (2012) report that change in proxy-rated QoL over 3 years was related only to change in 
function. The strong influence of mood for determining changes in self-reported QoL was a key 
feature of a 20-week follow up in care home residents (Hoe et al.,2009), whereas Livingston et al. 
(2012) reported that in an 18-month follow-up of those living with AD in the community, social 
relationships and mental health completely mediated the effect of disease severity on self-reported 
QoL. 
 
In exploring the associations between AD severity and QoL, it is important to consider the nature 
and content of the measures used to indicate the progression of AD. Whilst cognition, function and 
behaviour are commonly the focus for clinicians, it has been noted that each of these single 
indicators provide somewhat limited and conflicting information on typical AD progression pathways 
(Loveman et al., 2006). Dependence is a broader construct that reflects the level of assistance 
required by the person with AD and preliminary research supports associations with clinical 
endpoints and resource use (Brickman et al., 2002; Scherer, 2008; Zhu et al., 2008). It is possible that 
the use of a broader measure, such as dependence, may allow further evidence to emerge with 
regards to the association between AD progression and QoL outcomes.  To date, there have only 
been a few studies linking dependence and QoL in AD. McLaughlin et al (2010) demonstrated a 
moderate negative correlation between proxy ratings of QoL and dependence in 166 people with 
mild to moderate AD. Dependency has also been shown to predict the proxy QoL ratings made by 
staff caring for people with dementia in residential homes (Hoe et al., 2006). More recently, results 
from the cross-sectional Dependence in Alzheimer’s Disease England (DADE) study (Trigg et al., 
2012) suggest that self-report and proxy ratings of QoL and utility differ across levels of dependence 
such that those people who displayed greater dependence on others, were those who were rated as 
having a lower QoL. 
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The Dependence in Alzheimer’s Disease England 2 (DADE-2) study was an 18-month follow up to the 
DADE study and provided an opportunity to explore how ratings of QoL and utility change over time 
and in relation to changes in dependence and other indices of disease progression.  
 
Method 
 
Study design and patient sample 
 
The Dependence in AD in England (DADE) study was conducted across 18 UK sites and recruited 249 
people with mild, moderate or severe possible or probable Alzheimer’s disease according to the 
National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria. The evaluation of baseline QoL data from 
the DADE study has been reported previously (Jones et al, submitted). 
 
Eligible participants for the DADE-2 follow-up study were those who participated in the DADE study, 
were aged 50 years or over and were community-living or institutionalised. Exclusion criteria 
specified that participants should have no independent source of impairment that could lead to 
substantive needs for supportive care (due to confounding effects that this would have on the 
outcome measures) and should not be enrolled in interventional clinical trials of AD treatments. 
Each participant was required to have a knowledgeable informant who spent at least 4 hours per 
week caring for the patient. 
 
The study obtained Ethics Committee approval and was conducted in compliance with the 
Declaration of Helsinki and its amendments. Written informed consent was obtained for the follow-
up visit from all patients or caregivers and/or legally acceptable representatives, in accordance with 
local regulations.  
 
DADE-2 assessment visits were conducted after a period of 18 months (+/- 2 months) from the 
original DADE visit. All assessments were completed in one follow-up visit and were conducted by 
trained personnel on sites which are part of the DeNDRoN (Dementias & Neurodegenerative Disease 
Research Network) networks of the NHS. 
 
Measurements 
 
Quality of Life and Utility 
 
The 28-item DEMQOL and 31-item DEMQOL-Proxy (Smith et al., 2005) provide complementary 
methods for evaluating disease-specific health-related quality of life (HRQoL) in dementia. The 
DEMQOL and DEMQOL proxy have been shown to demonstrate psychometric properties 
comparable with the best available dementia-specific measures (Smith et al., 2007). The DEMQOL 
gives a score of 28-112 and the DEMQOL-Proxy a score of 31-124, with a higher score indicating 
better QoL. The DEMQOL proxy was completed for all participants and the patient-reported 
DEMQOL was only completed by patients with MMSE scores of ≥ 10 
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The EQ-5D (EUROQOL Group, 1990) was used to provide generic HRQoL utility ratings for the patient 
(self-rating and proxy). Utility preference weights were derived from a UK population (Dolan, 1997). 
The EQ-5D has been demonstrated to be applicable to people with mild to moderate dementia and 
caregivers as proxies (Kunz, 2010). EQ-5D proxy ratings were obtained for all patients in the study, 
whereas self-report ratings were only obtained from those with a MMSE score of ≥ 10. 
 
Dependence 
 
The Dependence Scale (DS; Stern et al., 1994) is a 13-item questionnaire developed to measure the 
amount of assistance AD patients need due to impairments in cognition, function and behaviour. It is 
administered to the caregiver and scale items assess relatively subtle types of dependence, such as 
need for reminders and cueing in daily activities, as well as grosser forms of dependence (e.g. need 
for assistance in self-care activities). The sum of items provides a total dependence score from 0-15, 
with a higher score indicating more dependence on others.  
 
Cognition 
 
The Mini-Mental State Examination (MMSE; Folstein et al., 1975) is a brief 30-point questionnaire 
that is used to screen for cognitive impairment. Scores ranging from 20-26 indicate some cognitive 
impairment; 10-19 indicate moderate to severe cognitive impairment, and below 10, very severe 
cognitive impairment.  
 
Function 
 
The Disability Assessment for Dementia (DAD; Gelinas et al., 1999) is a measure of instrumental and 
basic activities of daily living in AD patients. The scale contains 40 items and gives a total score from 
0-100, with a higher score indicating better activity performance. 
 
Behavioural disturbance 
 
The Neuropsychiatric Inventory (NPI; Cummings et al., 1994) assesses psychopathology in dementia 
patients. It evaluates the severity of neuropsychiatric disturbances common in dementia and scores 
range from 0-144, with higher scores representing more severe neuropsychiatric symptoms. 
 
Analysis 
 
All study endpoints are summarised using descriptive statistics. Effect sizes (ES) for change scores 
were calculated in relation to baseline standard deviations.  Pearson’s correlation coefficient was 
used to examine bivariate relationships between changes in study variables. Repeated measures t-
tests were used to assess significance of changes in study variables across the 18-month period. Due 
to multiple univariate analyses, p < 0.01 was used as the level for significance. To examine 
association between disease severity indicators and QoL, whilst controlling for baseline scores, 
ordinary least squares multiple regression was used. A stepwise method of entry was employed due 
to the exploratory nature of the analysis. A significance level of p < 0.01 was used for beta values in 
the regression of EQ-5D data due to kurtosis in the distribution of change scores. 
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Results 
 
For the purpose of the present analysis, 145 participants were included.  This is the number of 
participants who completed an assessment of dependence at DADE baseline and DADE-2 follow-up 
visits. Baseline demographics of these 145 patients and scores on all measures at both baseline and 
follow-up are summarized in Table 1.  Also provided, are the details of a smaller subsample of 
individuals (n = 70) who were able to complete follow-up assessments for self-reported QoL and 
utility (Subsample A). 
Assessment of Change in Study Variables 
 
Paired samples t-tests were used to explore significant differences in mean scale scores between 
baseline (T1) and 18-month follow-up (T2), for dependence, clinical variables and QoL outcomes (see 
Table 1). Dependence scores were significantly higher at T2 than T1 (t144 = -6.45, p < 0.001) showing a 
mean increase in sample dependence of 1.18 points (ES = 0.37) over the 18 months. 
There were also significant reductions in scores on the MMSE (ES = 0.46; t128 = 7.42, p < 0.001) and 
DAD (ES = 0.41;  t142 = 8.50, p < 0.001), indicating a reduction in cognitive ability and activities of daily 
living (ADL) function over time. There was no significant difference in NPI scores (t124 = 0.22, p > 0.05) 
across the two time points. A similar pattern of change was demonstrated within Subsample A, 
although the size of change was reduced across the measures. 
 
Insert Table 1 here 
 
Within the whole sample data, utility ratings on the EQ-5D proxy scale fell significantly by 0.1 points 
over the two time periods (ES = 0.34; t134 = 3.64, p < 0.001) whereas there was a significant increase 
of 4.84 points in QoL ratings on the DEMQOL-Proxy (ES = 0.34; t138 = -4.50, p < 0.001), suggesting 
that proxies were rating the QoL of participants as significantly better after 18 months. However 
within Subsample A, neither proxy nor self-reported QoL and utility ratings showed any significant 
mean change over the 18 months. 
 
Examination of the distribution of change scores on QoL and utility measures suggests that there is 
considerable individual variation across the 18-months. Figure 1 shows the distribution of QoL and 
utility change scores for the whole sample. Although there were no mean changes in QoL and utility 
within Subsample A, examination of the distribution of change scores on both proxy and self-report 
measures suggests that within this subsample there are positive and negative changes occurring for 
individuals. For the EQ-5D there were approximately equal proportions of participants who reported 
utility values better, worse or the same as baseline (27.6%, 39.1% and 33.3% respectively). For the 
EQ-5D proxy 45.6% of the sample were judged as having lower utility but there were almost a third 
(30.9%) for whom proxies reported an improvement in utilty. For the DEMQOL self-report 40% of 
participants reported a reduction in QoL however this was offset by a larger proportion (57.1%) 
reporting a QoL improvement. The DEMQOL proxy demonstrated a high proportion of participants 
as having an improved (55.1%) as opposed to reduced (40.6%) QoL.  
  
Insert Figure 1 here 
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Associations between Change Scores  
 
Pearson’s correlation coefficients were used to explore bivariate associations between change 
scores (Time 2 – Time 1) for dependence, changes in clinical indicators and changes in QoL and utility 
measures (see Table 2). Changes in DS scores showed significant bivariate associations with changes 
in MMSE (r128 = -0.26, p < 0.01) and DAD scores (r142 = -0.42, p < 0.001) such that worsening cognition 
and function were associated with increases in dependence. There was little association between 
the change scores on the different QoL and utility measures. Only the change scores on the self-
report EQ-5D and DEMQOL were significantly correlated (r68 = 0.43, p < 0.01). 
Insert Table 2 here 
Changes in Disease Severity and Associations with QoL Outcomes 
 
Changes in dependence showed no significant bivariate associations with changes in any of the QoL 
or utility measures (see Table 2). To further explore any relationship between changes in 
dependence and QoL outcomes, the sample was split into two groups according to DS change 
scores: negative/no change (DS change -7 to 0) and positive change in scores (DS change 1-7). 
Independent t-tests confirmed that there were no significant differences between the two groups 
for any of the QoL or utility scales (see Table 3). 
Insert Table 3 here 
As shown in Table 2, Pearson correlations between change scores on QoL outcomes and changes on 
the MMSE, DAD and NPI were calculated. These suggest that changes on the EQ-5D, EQ-5D proxy 
and DEMQOL are not significantly associated with changes in any of these three clinical indicators. 
Changes in the DEMQOL-Proxy displayed weak but significant associations with changes on the NPI 
(r119 = -0.29, p < 0.01) such that increases in the severity of neuropsychiatric disturbances over time 
are associated with a reductions in QoL ratings by proxies. 
Multivariate Analysis of QoL and Utility Changes 
 
The factors associated with changes in QoL and utility were further explored using multiple linear 
regression.  For each QoL and utility indicator a stepwise regression was conducted whereby scores 
for DS change, MMSE change, DAD change and NPI change were considered for entry into an 
exploratory model. Alongside these four possible explanatory variables, the baseline scores for the 
particular QoL or utility measure were also entered, to control for the fact that the magnitude of 
change can be dependent on baseline ratings. Final models are shown in Table 4. 
Insert Table 4 here 
 
For the EQ-5D self-report and DEMQOL, no measure of disease progression was able to account for 
variation in QoL or utility. Only baseline ratings from these two measures were significant within the 
final regression models. There was an inverse relationship, such that lower baseline scores were 
predictive of larger increases in QoL and higher baseline scores with lower improvements or 
deterioration in QoL. For changes in EQ-5D proxy ratings, baseline scores and MMSE change scores 
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were significant explanatory variables, such that lower baseline scores and improvement in 
cognition were associated with larger increases in proxy utility ratings. For changes in DEMQOL-
Proxy ratings, baseline scores and change in NPI scores were significant such that lower baseline 
scores and decreasing neuropsychiatric disturbance were associated with larger improvements in 
QoL ratings.  
Discussion 
 
The study aimed to explore changes in QoL and utility over an 18-month period and its relationship 
with different indices of disease progression, including dependence. Findings suggest that there is a 
large amount of individual variation in QoL and utility, with over 50% of participants reporting 
maintenance or improvement in QoL and utility. The mean change data is inconclusive across the 
different measures of QoL and utility and different conclusions can be drawn depending on which 
measure is used.  
 
Both of the self-report measures, the EQ-5D and the DEMQOL, failed to show group-level change 
over the 18 months. However the self-report data was obtained from only those participants with 
higher MMSE scores. This means that those who deteriorated significantly over the 18-months were 
unlikely to provide self-report QoL information at follow up. The data supports the suggestion that 
the self-report subsample included participants who experienced less deterioration over time and 
the proxy QoL and utility ratings for this sample also showed no mean change. Within the whole 
sample data, the proxy ratings of QoL and utility provided conflicting results. The EQ-5D proxy data 
suggested an overall decline in utility for the whole sample and yet the DEMQOL-Proxy data 
indicated an overall improvement in life quality. Measures of cognition (MMSE), function (DAD) and 
dependence (DS) all displayed significant decline over the 18 months in both the whole sample and 
the self-report subsample, suggesting that dementia had progressed. The only marker of disease 
severity that showed no significant change was behavioural disturbance (NPI).  
 
Although cross-sectional data has suggested links between dependence and QoL (Trigg et al., 2012) 
these relationships were not evident in the change scores. Changes on the DS showed no association 
with change in QoL or utility within univariate or multivariate analyses. Changes to EQ-5D proxy 
ratings were partly explained by changing cognition whereas changes on the DEMQOL-Proxy were 
associated with changes in the severity of behavioural disturbance, although these associations were 
relatively weak. The association between the DEMQOL-Proxy and NPI may explain why the 
DEMQOL-Proxy was the one measure that actually reported an overall improvement in QoL for the 
whole sample. NPI scores remained stable over the 18 months and this lack of deterioration may 
have led to more positive evaluations of life quality by the caregiver. Both of the self-report 
measures of QoL and utility failed to show significant associations with changes to any of the 
measures of disease progression. In fact the strongest predictor of change on each of the four QoL 
outcomes was the baseline score for that measure, such that higher baseline scores were more likely 
to be reduced at follow-up and vice versa. This finding has been replicated in other cohort studies 
(Selwood et al., 2005; Hoe et al., 2009; Vogel et al., 20012) and may reflect regression towards the 
mean in longitudinal QoL data. In order to avoid misinterpreting changes in QoL, it is important that 
studies assessing the impact of intervention or treatment carefully control for baseline 
measurements. 
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The finding that QoL and utility do not inevitably decline as dementia progresses concurs with 
several other studies that have shown similar results, using both proxy and self-report measures 
(Selwood et al., 2005; Missotten et al., 2007; Hoe et al., 2009; Livingston et al., 2012; Heggie et al., 
2012). Several reasons have been proposed for the lack of a direct link between changes in disease 
severity and QoL outcomes. For self-report measures of QoL it may be that reduced insight 
suppresses the impact of worsening symptoms and functioning on the QoL reported by the person 
with AD (Trigg et al., 2011). Alternatively it may be that the person with AD is able to accommodate 
and adapt to gradual changes in cognition, function and behaviour, thus reducing the impact on 
more holistic outcomes such as wellbeing and life quality (Livingston et al., 2012). Theories such as 
response shift (Sprangers & Schwartz, 1999) also provide an explanatory mechanism whereby the 
person adjusts expectations and internal standards, in response to deterioration in health, thereby 
reducing fluctuations in self-reported QoL. Research also indicates that caregiver factors such as 
burden and depression may influence the QoL ratings that proxies provide (Conde-Sala et al., 2009: 
Schiffczyk et al., 2010). It may also be that participation in studies and trials impacts on patient and 
caregiver perceptions of support and this might serve to buffer the QoL reports obtained. A further 
consideration is the impact of participant drop-out within longitudinal studies. It may be that those 
who experience significant declines in QoL are also those more likely to be lost to follow-up.  
  
Although mean self-report scores on the DEMQOL and the EQ-5D showed no significant group-level 
changes, there was considerable evidence of individual change. Previous studies have found the EQ-
5D and other self-report measures to be responsive to changes in the QoL of people with dementia 
(Hounsome et al., 2011; Perales et al., 2013), which suggests that such change is not solely 
attributable to measurement error. In fact the EQ-5D and DEMQOL self-report were the only QoL 
and utility measures to display a significant association. The correlation between the change scores 
on these different measures was moderate in size and suggests that people with AD are able to 
provide consistent and meaningful information via self-report. The challenge for future research is to 
determine the key factors that influence these ratings. 
 
Evidence from this study and others (Missotten et al., 2007; Livingston et al., 2012; Vogel et al., 
2012) points to the lack of a clear direct relationship between changes in disease severity and 
changes in QoL or utility. The maintenance and improvement of QoL reported by many people with 
AD in this study, suggests the possible buffering influence of other psychological, social and 
environmental factors. These need exploring if we are to properly understand how and why QoL 
changes for the individual across the natural course of the disease and in response to treatment and 
intervention. We also need to be mindful of the fact that different QoL and utility measures may 
lead us to very different conclusions about the direction, magnitude and causes of change. Careful 
interpretation is needed when drawing conclusions from QoL outcomes and individual scores should 
be considered alongside sample means in order to capture the true nature of changes. 
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Table 1: Demographics, clinical status and QoL/utility scores of all participants included in follow-up and the subsample who completed self-reported 
QoL/utility follow-up (Subsample A) 
  Baseline Scores (T1) 18 Month Follow-up (T2) Change Scores (T2-T1) 
 n Mean SD Min Max n Mean SD Min Max n Mean SD Min Max P 
value 
Partial 
ƞ2 
Whole Sample                  
Age 145 77.78 9.24 53 102             
Male 57                 
Female 88                 
DS 145 7.79 3.14 0 14 145 8.98 3.44 0 15 145 1.18 2.21 -7 7 <0.001 0.22 
MMSE 145 14.99 7.00 3 26 129 12.64 8.57 0 27 129 -3.26 4.99 -23 9 <0.001 0.30 
DAD 144 47.26 28.58 0 100 144 35.41 29.54 0 100 143 -11.80 16.60 -71.18 50 <0.001 0.33 
NPI 131 20.96 18.11 1 106 136 20.80 18.60 1 119 125 -0.37 18.53 -53 43 ns  
DEMQOL-Proxy 143 97.26 14.11 60 123 141 102.48 11.61 71 124 139 4.84 12.68 -32 48 <0.001 0.12 
EQ-5D Proxy 140 0.70 0.29 -0.09 1 140 0.60 0.33 -0.17 1 135 -0.10 0.32 -1.02 0.81 <0.001 0.09 
                  
Subsample A                  
Age 70 78.19 8.48 53 102             
Male 31                 
Female 39                 
DS 70 5.99 2.60 0 13 70 6.77 2.84 0 15 70 0.78 2.32 -7 7 <0.01 0.10 
MMSE 70 20.69 3.45 10 26 70 19.40 4.67 10 27 70 -1.28 3.84 -11 9 <0.01 0.10 
DAD 70 65.78 22.24 15 100 70 57.44 22.54 5.41 100 70 -8.33 16.23 -54.12 31.35 <0.001 0.21 
NPI 61 16.13 15.72 1 86 65 17.68 15.65 1 89 58 1.56 15.57 -49 40 ns  
DEMQOL-Proxy 70 97.61 14.06 63 123 69 100.38 12.56 71 124 69 2.51 11.39 -32 38.57 ns  
EQ-5D Proxy 69 0.76 0.23 0.05 1 69 0.74 0.23 -0.17 1 68 -0.02 0.22 -0.6 0.61 ns  
DEMQOL 70 95.20 13.73 54 112 70 96.43 12.35 63 112 70 1.22 8.60 -24 18 ns  
EQ-5D  70 0.81 0.22 0 1 69 0.83 0.18 0.01 1 69 0.02 0.21 -0.61 0.66 ns  
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ns = non-significant 
DS = Dependence Scale; MMSE = Mini-Mental State Examination; DAD = Disability Assessment for Dementia;  
NPI = Neuropsychiatric Inventory;  
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Figure 1: Change from baseline scores on QoL and utility measures 
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Table 2: Pearson correlations between change scores on study measures 
 
 
 
 
 
 
 
 
 
 
* p < 0.01 
DS = Dependence Scale;  MMSE = Mini-Mental State Examination; DAD = Disability Assessment for Dementia;  
NPI = Neuropsychiatric Inventory 
  
 
 
DS 
Change 
EQ-5D 
Change 
EQ-5D 
Proxy 
Change 
DEMQOL 
Change 
DEMQOL
- Proxy 
Change 
MMSE 
Change 
DAD 
Change 
EQ-5D Change  -.10       
EQ-5D Proxy Change -.12 .19      
DEMQOL Change -.08 .43* .21     
DEMQOL-Proxy Change -.01 .04 .12 .17    
MMSE Change -.26* .02 .22 .03 .08   
DAD Change -.42* .06 .13 -.09 .04 .43*  
NPI Change -.14 .09 -.05 -.26 -.29* -.18 -.25* 
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Table 3: QoL change scores by two Dependence Scale change groups: reduced dependence/no change and increased dependence 
 
 
 
 
 
 
 
 
ns = p > 0.05 
DS = Dependence Scale  
 
 
 
  
 DS Change -7 to 0 DS Change 1-7  t-test 
 n Mean SD n Mean SD p 
EQ-5D Change 35 0.04 0.24 34 0 0.18 ns 
EQ-5D Proxy Change 55 -0.06 0.23 80 -0.12 0.37 ns 
DEMQOL Change 35 2.14 9.85 35 0.31 7.16 ns 
DEMQOL-Proxy Change 56 4.38 10.99 83 5.16 13.76 ns 
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Table 4: Linear regression models for QoL and utility change: contribution of change in disease severity and baseline QoL/utility ratings 
 
 
 
 
 
 
 
 
 
 
* P < 0.05 
** p < 0.001 
MMSE = Mini-Mental State Examination; NPI = Neuropsychiatric Inventory 
 
Score Model 
Significance 
R2 Variable Beta SE Beta 
 
Standardised 
beta 
t 
        
EQ5D Change F(1,56) = 31.25**  0.35 (Constant) 0.50 0.09  5.49** 
   EQ5D baseline -0.60 0.1 -0.59 -5.59** 
        
EQ5D Proxy Change F(2,100) = 15.86** 0.24 (Constant) 0.26 0.06  3.92** 
   EQ5D Proxy baseline -0.42 0.08 -0.42 -4.87** 
   MMSE change 0.01 0.005 0.20 2.30* 
        
DEMQOL Change F(1,56) = 13.90** 0.19 (Constant) 27.39 7.07  3.87** 
   DEMQOL baseline -0.27 0.07 -0.44 -3.72** 
        
DEMQOL-Proxy Change F(1,104) = 12.43** 0.19 (Constant) 58.80 6.64  8.85** 
   DEMQOL-Proxy baseline -0.56 0.06 0.61 -8.34** 
   NPI change -0.15 0.06 0.18 -2.48* 
        
